Literature DB >> 24580887

Higher proportion of G2P[4] rotaviruses in vaccinated hospitalized cases compared with unvaccinated hospitalized cases, despite high vaccine effectiveness against heterotypic G2P[4] rotaviruses.

J Matthijnssens1, M Zeller, E Heylen, S De Coster, J Vercauteren, T Braeckman, K Van Herck, N Meyer, J-Y Pirçon, M Soriano-Gabarro, M Azou, H Capiau, J De Koster, A-S Maernoudt, M Raes, L Verdonck, M Verghote, A Vergison, P Van Damme, M Van Ranst.   

Abstract

The overall vaccine effectiveness of the monovalent rotavirus vaccine in an observational, prospective, multicentre, hospital-based case-control study in Belgium (RotaBel) was 90%. However, rotavirus genotype and co-infecting pathogens are important parameters to take into account when assessing vaccine effectiveness. In this study we specifically investigated the effect of rotavirus genotypes and co-infecting pathogens on vaccine effectiveness of the monovalent vaccine. In addition, we also investigated the effect of co-infecting pathogens on disease severity. From February 2008 to June 2010 stool samples of rotavirus gastroenteritis cases of a random sample of 39 Belgian hospitals were collected and subsequently genotyped. Fisher's exact tests were performed to investigate the relationships between rotavirus genotype, co-infecting pathogens and disease severity. The vaccine effectiveness of a full series of the monovalent rotavirus vaccine against hospitalized rotavirus gastroenteritis caused by G1P[8] rotavirus strains was 95% (95% CI 77.5-98.7). Against G2P[4], the vaccine effectiveness was 85% (95% CI: 63.7-93.8). G4P[8]- and G3P[8]-specific vaccine effectiveness was 90% (95% CI 19.2-98.7) and 87% (95% CI -5.2 to 98.4), respectively. A post-hoc analysis showed that the genotype distribution was significantly related to the vaccination status (p <0.001), whereby G2P[4] strains were proportionally more prevalent in vaccinated cases than in unvaccinated cases. No statistical associations were found between co-infection status and vaccination status, Vesikari severity score or rotavirus genotype. The high vaccine effectiveness against the individual genotypes implies robust protection of the monovalent rotavirus vaccine against hospitalized rotavirus gastroenteritis caused by the major human rotavirus genotypes. The prevalence of G2P[4] requires continued monitoring.
© 2014 The Authors Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Keywords:  Co-infection; G2P[4]; disease severity; rotavirus vaccine effectiveness; selective pressure

Mesh:

Substances:

Year:  2014        PMID: 24580887     DOI: 10.1111/1469-0691.12612

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  27 in total

1.  Evaluation of the Influence of Gastrointestinal Coinfections on Rotavirus Vaccine Effectiveness in Botswana.

Authors:  Margaret Mokomane; Jacqueline E Tate; Andrew P Steenhoff; Mathew D Esona; Michael D Bowen; Kwana Lechiile; Jeffrey M Pernica; Ishmael Kasvosve; Umesh D Parashar; David M Goldfarb
Journal:  Pediatr Infect Dis J       Date:  2018-03       Impact factor: 2.129

2.  Effect of monovalent rotavirus vaccine on rotavirus disease burden and circulating rotavirus strains among children in Morocco.

Authors:  Mohammed Benhafid; Nezha Elomari; Meryem Azzouzi Idrissi; Ahmed Rguig; Jon R Gentsch; Umesh Parashar; Rajae Elaouad
Journal:  J Med Virol       Date:  2015-03-05       Impact factor: 2.327

3.  Increasing detection of rotavirus G2P[4] strains in Nizhny Novgorod, Russia, between 2016 and 2019.

Authors:  Olga V Morozova; Tatiana A Sashina; Natalia V Epifanova; Alexander Yu Kashnikov; Nadezhda A Novikova
Journal:  Arch Virol       Date:  2020-10-20       Impact factor: 2.574

4.  Emerging OP354-Like P[8] Rotaviruses Have Rapidly Dispersed from Asia to Other Continents.

Authors:  Mark Zeller; Elisabeth Heylen; Susan Damanka; Corinna Pietsch; Celeste Donato; Tsutomu Tamura; Ruta Kulkarni; Ritu Arora; Nigel Cunliffe; Leena Maunula; Christiaan Potgieter; Sana Tamim; Sarah De Coster; Elena Zhirakovskaya; Salwa Bdour; Helen O'Shea; Carl D Kirkwood; Mapaseka Seheri; Martin Monene Nyaga; Jeffrey Mphahlele; Shobha D Chitambar; Ron Dagan; George Armah; Nina Tikunova; Marc Van Ranst; Jelle Matthijnssens
Journal:  Mol Biol Evol       Date:  2015-04-08       Impact factor: 16.240

5.  Rotavirus vaccine effectiveness and impact in Uzbekistan, the first country to introduce in central Asia.

Authors:  Umid Eraliev; Renat Latipov; Dilorom Tursunova; Annemarie Wasley; Danni Daniels; Umed Ismoilov; Manzura Akramova; Mehri Sultanova; Dilbar Yuldashova; Bahodir Barakaev; Vazira Mutalova; Laziz Tuychiev; Erkin Musabaev; Said Sharapov; Boris Pleshkov; Dovile Videbaek; Shahin Huseynov; Kamola Safaeva; Slavica Mijatovic-Rustempasic; Michael D Bowen; Umesh D Parashar; Margaret M Cortese
Journal:  Hum Vaccin Immunother       Date:  2020-08-05       Impact factor: 3.452

6.  Do Rotavirus Strains Affect Vaccine Effectiveness? A Systematic Review and Meta-analysis.

Authors:  Jordan E Cates; Avnika B Amin; Jacqueline E Tate; Ben Lopman; Umesh Parashar
Journal:  Pediatr Infect Dis J       Date:  2021-12-01       Impact factor: 2.129

7.  Effectiveness of a monovalent rotavirus vaccine in infants in Malawi after programmatic roll-out: an observational and case-control study.

Authors:  Naor Bar-Zeev; Lester Kapanda; Jacqueline E Tate; Khuzwayo C Jere; Miren Iturriza-Gomara; Osamu Nakagomi; Charles Mwansambo; Anthony Costello; Umesh D Parashar; Robert S Heyderman; Neil French; Nigel A Cunliffe
Journal:  Lancet Infect Dis       Date:  2015-01-29       Impact factor: 25.071

8.  Incidence of rotavirus and circulating genotypes in Northeast Brazil during 7 years of national rotavirus vaccination.

Authors:  Ricardo Q Gurgel; Alberto De Juan Alvarez; Alda Rodrigues; Robergson R Ribeiro; Sílvio S Dolabella; Natanael L Da Mota; Victor S Santos; Miren Iturriza-Gomara; Nigel A Cunliffe; Luis E Cuevas
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

9.  Did Large-Scale Vaccination Drive Changes in the Circulating Rotavirus Population in Belgium?

Authors:  Virginia E Pitzer; Joke Bilcke; Elisabeth Heylen; Forrest W Crawford; Michael Callens; Frank De Smet; Marc Van Ranst; Mark Zeller; Jelle Matthijnssens
Journal:  Sci Rep       Date:  2015-12-21       Impact factor: 4.379

Review 10.  Effectiveness of rotavirus vaccines against rotavirus infection and hospitalization in Latin America: systematic review and meta-analysis.

Authors:  Victor S Santos; Daniella P Marques; Paulo R S Martins-Filho; Luis E Cuevas; Ricardo Q Gurgel
Journal:  Infect Dis Poverty       Date:  2016-08-12       Impact factor: 4.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.